Corona Virus Disease 2019 Cohort Study
Study on the Influence of Corona Virus Disease 2019 on Obstetric Outcome and Offspring Development
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The main questions it aims to answer are:
- Collect the information about Corona Virus Disease 2019 infection and medication of pregnant women to establish a birth cohort, and analyze the correlation between Corona Virus Disease 2019 infection during pregnancy and adverse pregnancy outcomes and birth outcomes.
- The offspring born in this cohort were followed up to analyze the effects of Corona Virus Disease 2019 infection during pregnancy on the nervous system development of the offspring.
Researchers will compare Corona Virus Disease 2019 infection group and uninfected group during pregnancy to see if Corona Virus Disease 2019 infection has adverse effects on pregnant women and their offspring.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jie Chen, Doctorate
- Phone Number: 86 18615656606
- Email: 202216407@mail.sdu.edu.cn
Study Contact Backup
- Name: Yinuo Song
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
Study Locations
-
-
-
JiNan, China
- Recruiting
- Jinan Maternity and Child Health Care Hospital
-
Contact:
- Yinuo Song, Master
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
-
JiNan, China
- Recruiting
- Qianfoshan Hospital
-
Contact:
- Yinuo Song, Master
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
-
JiNan, China
- Recruiting
- Qilu Hospital of Shandong University
-
Contact:
- Yinuo Song, Master
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
-
JiNan, China
- Recruiting
- Shandong Provincial Maternity and Child Health Care Hospital
-
Contact:
- Yinuo Song, Master
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
-
-
Shandong
-
JiNan, Shandong, China, 250000
- Recruiting
- The Second Hospital of Shandong University
-
Contact:
- Yinuo Song, Master
- Phone Number: 86 17861203953
- Email: 363197039@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Conduct regular prenatal examinations in the hospital and establish a pregnancy and childbirth health manual, planning for pregnant women who are hospitalized for delivery;
- Conduct regular physical examinations in the hospital and establish a children's health manual for infants.
- Age ≥ 18 years old
Exclusion Criteria:
- Concomitant tumor related diseases;
- Individuals with severe mental disorders.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure the developmental outcomes of the nervous system using the Gesell Development Plan (GDS) or the 0-6-year-old Child Development Scale (DST).
Time Frame: From 6 months of birth to completion of the GDS measurement, the assessment is up to 6 months
|
GDS mainly diagnoses four abilities: motor ability, object ability, speech ability, and human ability,.
Thus, the development quotient of four aspects can be obtained.
If the development quotient is below 65-75, it indicates serious backwardness.
The DST assessment includes five functional areas: gross motor, fine motor, language, adaptability, and social behavior, to obtain developmental quotient, which is used to measure the developmental behavior of children and evaluate their level of development.
A score above 130 indicates excellent performance, and a score below 70 indicates intellectual development disorder.
|
From 6 months of birth to completion of the GDS measurement, the assessment is up to 6 months
|
|
Pregnancy complications or comorbidities
Time Frame: Starting prenatal examination until discharge,the evaluation take up to 10 months
|
Obtain relevant information from medical records.
Pregnancy complications refer to non pregnancy related diseases that occur before or during pregnancy, while pregnancy complications refer to any diseases that coexist with pregnancy.
|
Starting prenatal examination until discharge,the evaluation take up to 10 months
|
|
Obtain neonatal outcomes.
Time Frame: The evaluation period from birth to discharge is up to 1 week
|
Obtain neonatal outcomes from neonatal records, including macrosomia, neonatal asphyxia, fetal distress, low birth weight infants, and deformed infants.
|
The evaluation period from birth to discharge is up to 1 week
|
|
Comprehensive results of COVID-19 infection during pregnancy
Time Frame: Baseline data were obtained when participants were enrolled in the study and assessed for up to 1 years
|
Through questionnaires, medical records and test sheets, The investigators can get whether the pregnant women have been infected with COVID-19 during pregnancy, the time of infection, pregnancy weeks, symptoms, etc.
|
Baseline data were obtained when participants were enrolled in the study and assessed for up to 1 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delivery method
Time Frame: The evaluation period from admission to delivery to discharge is up to 1 week
|
Natural delivery, vaginal surgery, or curettage.
|
The evaluation period from admission to delivery to discharge is up to 1 week
|
|
Estimation of bleeding volume
Time Frame: The evaluation period from admission to delivery to discharge is up to 1 week
|
Total amount of bleeding during or 24 hours postpartum.
|
The evaluation period from admission to delivery to discharge is up to 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Fanzhen Hong, Doctorate, The Second Hospital of Shandong University
- Study Director: Xia Luo, Doctorate, Qilu Hospital of Shandong University
- Study Director: Yueqin Xu, Doctorate, Qianfoshan Hospital
- Study Director: Qiuhong Yang, Doctorate, Jinan Maternity and Child Health Care Hospital
- Study Chair: Jie Chen, Doctorate, Shandong University
- Principal Investigator: Yinuo Song, Master, Shandong University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LL202303018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.